News & Insights

Oxford Technology & Innovations EIS Fund (OTIF) and co-investors participate in ONI’s $75m Series B financing

  • ONI has closed a $75m Series B financing led by US investors ARCH Venture Partners and Casdin Capital.
  • ONI is a pioneer in observing single molecules in living cells. The Company’s first product, the Nanoimager, is the world’s first desktop, super-resolution, single-molecule imaging platform capable of visualising and tracking individual molecules in complex systems such as nanoparticles, living cells and tissue with 20nm resolution.
  • The Series B funds will be used to build a product portfolio that harnesses the Company’s innovative technology to unlock new possibilities in therapeutic and diagnostic development, as well as basic life sciences research.
Read post

Oxford Technology & Innovations EIS Fund (OTIF) invests £1.6m into University of Oxford spinout company OrganOx Ltd

  • OrganOx Ltd. is commercialising the metra L, the world’s first normothermic liver perfusion device.
  • OTIF’s investment was advised by Oxford Investment Consultants LLP and was part of a £6.4 million round led by Oxford Investment Consultants LLP.
  • Funding will accelerate a number of programmes in OrganOx’s R&D pipeline, with a Phase I clinical trial for a normothermic kidney perfusion device due to start later this year.
  • This investment in OrganOx Ltd., brings the total funds invested by OTIF in the Company to £5.6m.
Read post